NCT04209855: A trial that was reported late by AbbVie
This trial has reported, although it was 124 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04209855 |
|---|---|
| Title | MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 31, 2019 |
| Completion date | March 6, 2023 |
| Required reporting date | March 5, 2024, midnight |
| Actual reporting date | July 8, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 124 |